미국의 CLIA 내분비 검사 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 검사 유형별, 임상 현장별 및 부문별 예측(2026-2033년)

U.S. CLIA Endocrine Testing Market Summary

The U.S. CLIA endocrine testing market size was estimated at USD 14.06 billion in 2025 and is projected to reach USD 34.38 billion by 2033, growing at a CAGR of 11.94% from 2026 to 2033. Market growth is supported by the increasing prevalence of chronic and hormonal disorders and the need for high sensitivity and analytical accuracy in hormone detection.

Advancements in automated CLIA platforms are enhancing diagnostic efficiency. Furthermore, regulatory compliance under the Clinical Laboratory Improvement Amendments ensures standardized testing quality, supporting consistent adoption of endocrine testing services in the U.S.

The rising burden of chronic and hormonal disorders is significantly increasing the demand for endocrine testing in the U.S. Conditions such as diabetes, thyroid dysfunction, and polycystic ovary syndrome (PCOS) are becoming more prevalent due to aging populations, sedentary lifestyles, obesity, and environmental factors. According to the report published by the World Health Organization in January 2026, PCOS affects approximately 10-13% of reproductive-age women globally, with nearly 70% of cases remaining undiagnosed, indicating a substantial gap in diagnostic testing. Moreover, the National Center for Biotechnology Information reports that at least 5% of adults in the U.S. are affected by endocrine disorders, including hypothyroidism, osteopenia, and vitamin D deficiency. This growing clinical burden is driving consistent demand for advanced, high-sensitivity endocrine testing across CL0IA-certified laboratories in the U.S.

Advancements in automated chemiluminescence immunoassay (CLIA) platforms are significantly improving the efficiency, scalability, and precision of endocrine testing in the U.S. Modern CLIA analyzers are designed for high-throughput processing, minimal manual intervention, and rapid turnaround times, enabling laboratories to handle large test volumes while reducing operational errors. These systems support automated sample handling, calibration, and result interpretation, which enhances reproducibility and consistency in hormone analysis. For instance, in March 2026, F. Hoffmann-La Roche Ltd. received a CLIA moderate-complexity classification from the U.S. Food and Drug Administration for its Ionify steroid assays integrated with the cobas Mass Spec solution, enabling routine clinical laboratories to perform highly accurate steroid hormone testing through automated, standardized workflows. These advancements are accelerating the adoption of high-throughput, automated endocrine testing solutions across U.S. CLIA-certified laboratories, supporting improved diagnostic efficiency and scalability.

Regulatory compliance under the Clinical Laboratory Improvement Amendments is supporting the growth of the U.S. CLIA endocrine testing industry by ensuring standardized testing quality, accuracy, and reliability across laboratories. These regulations mandate strict quality control, proficiency testing, and personnel standards, reducing diagnostic errors and improving clinical confidence in hormone test results. The classification of tests based on complexity also enables laboratories to expand service offerings while maintaining compliance. This structured framework encourages the adoption of advanced automated testing platforms. It promotes consistency in diagnostic practices, ultimately increasing test volumes and supporting the sustained expansion of endocrine testing services across the U.S.

The growth of large reference laboratories, combined with favorable reimbursement and insurance coverage, is supporting the expansion of the U.S. CLIA endocrine testing market. Major diagnostic laboratories are increasing capacity and adopting automation, enabling centralized testing models with higher throughput and faster turnaround times. This enhances operational efficiency and supports large-scale endocrine testing. In parallel, reimbursement policies in the U.S. encourage the use of diagnostic services by improving affordability and access. Although pricing pressures persist, consistent insurance coverage continues to sustain testing demand, contributing to steady market growth.

U.S. CLIA Endocrine Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. CLIA endocrine testing market report based on product, testing type, and clinical setting:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Kits & Reagents
• Instruments
• Testing Type Outlook (Volume, Number of Tests; Revenue, USD Million, 2021 - 2033)
• Thyroid Testing
  • TSH
  • Free T4 (fT4)
  • T4 (Total)
  • Free T3 (FT3)
  • T3 (Total)
  • Anti-TPO
  • Anti-Tg
  • Thyroglobulin (Tg)
  • T3 Resin Uptake
• Hormone Testing
  • FSH
  • hCG
  • Testosterone
  • Progesterone
  • Prolactin
  • Estradiol E2
  • Luteinizing Hormone (LH)
  • Sex Hormone-Binding Globulin (SHBG)
  • DHEA-S (dehydroepiandrosterone sulfate)
  • Human growth hormone (HGH)
  • Anti-Mullerian Hormone (AMH)
• Bone Health
  • Vitamin D
  • Parathyroid hormone (PTH)
  • Serum CTX (Carboxy-terminal collagen crosslinks)
  • NTx (N-telopeptide)
  • Osteocalcin
  • Alkaline phosphatase (ALP)
• Clinical Setting Outlook (Volume, Number of Tests; Revenue, USD Million, 2021 - 2033)
• OBGYN office
• Fertility / IVF Clinics
• Physician office labs (POLs)
• Hospital Labs Small (<100 beds)
• Hospital Labs Large (>500 beds)
• Others

Table of Contents

Chapter 1. U.S. CLIA Endocrine Testing Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Method
    • 1.1.1.2. Testing Type Segment
    • 1.1.1.3. Clinical Settings Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. U.S. CLIA Endocrine Testing Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product Snapshot
• 2.3. Testing Type Snapshot
• 2.4. Clinical Settings Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. U.S. CLIA Endocrine Testing Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Increasing prevalence of chronic and hormonal disorders
  • 3.4.2. Need for high sensitivity and analytical accuracy in hormone detection.
  • 3.4.3. Advancements in automated CLIA platforms
  • 3.4.4. Regulatory compliance under the clinical laboratory improvement amendments
• 3.5. Market Restraint Analysis
  • 3.5.1. High cost of advanced CLIA platforms and testing infrastructure
  • 3.5.2. Stringent regulatory and compliance requirements
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. U.S. CLIA Endocrine Testing Market: Product Estimates & Trend Analysis

• 4.1. U.S. CLIA Endocrine Testing Market: Product Dashboard
• 4.2. U.S. CLIA Endocrine Testing Market: Product Movement Analysis
• 4.3. U.S. CLIA Endocrine Testing Market by therapy, Revenue
• 4.4. Kits & Reagents
  • 4.4.1. Kits & Reagents market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Instruments
  • 4.5.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. CLIA Endocrine Testing Market, By Testing Type, 2021 - 2033 Value (USD Million), Volume (Number of tests)

• 5.1. Thyroid Testing market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.1.1. TSH market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.1.2. Free T4 (fT4) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.1.3. T4 (Total) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.1.4. Free T3 (FT3) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.1.5. T3 (Total) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.1.6. Anti-TPO market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.1.7. Anti-Tg market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.1.8. Thyroglobulin (Tg) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.1.9. T3 Resin Uptake market estimates and forecasts 2021 to 2033 (USD Million)
• 5.2. Hormone Testing market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.1. FSH market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.2. hCG market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.3. Testosterone market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.4. Progesterone market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.5. Prolactin market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.6. Estradiol E2 market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.7. Luteinizing Hormone (LH) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.8. Sex Hormone-Binding Globulin (SHBG) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.9. DHEA-S (dehydroepiandrosterone sulfate) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.10. Human growth hormone (HGH) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.2.11. Anti-Mullerian Hormone (AMH) market estimates and forecasts 2021 to 2033 (USD Million)
• 5.3. Bone Health market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.1. Vitamin D market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.2. Parathyroid hormone (PTH) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.3. Serum CTX (Carboxy-terminal collagen crosslinks) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.4. NTx (N-telopeptide) market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.5. Osteocalcin market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.6. Alkaline phosphatase (ALP) market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. CLIA Endocrine Testing Market, Clinical Setting by Testing Type, 2021 - 2033 Value (USD Million), Volume (Number of tests)

• 6.1. U.S. CLIA Endocrine Testing Market: Testing Type, Value (USD Million), Volume (Number of tests) Dashboard
• 6.2. U.S. CLIA Endocrine Testing Market: Testing Type, Value (USD Million), Volume (Number of tests) Movement Analysis
• 6.3. U.S. CLIA Endocrine Testing Market by Testing Type, Value (USD Million), Volume (Number of tests)
• 6.4. OBGYN office
  • 6.4.1. OBGYN office market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
• 6.5. Physician office labs (POLs)
• 6.6. Physician office labs (POLs) market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
• 6.7. Hospital Labs Small (<100 beds)
  • 6.7.1. Hospital Labs Small (<100 beds) market estimates and forecasts 2021 to 2033 (USD Million)(Number of tests)
• 6.8. Hospital Labs Medium (100-500 beds)
  • 6.8.1. Hospital Labs Medium (100-500 beds) market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)
• 6.9. Hospital Labs Large (>500 beds)
  • 6.9.1. Hospital Labs Large (>500 beds) market estimates and forecasts 2021 to 2033 (USD Million) (Number of tests)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
• 7.4. List of key distributors and channel partners
• 7.5. Key customers
• 7.6. Key company market share analysis, 2025
  • 7.6.1. F. Hoffmann-La Roche Ltd
    • 7.6.1.1. Company overview
    • 7.6.1.2. Financial performance
    • 7.6.1.3. Product benchmarking
    • 7.6.1.4. Strategic initiatives
  • 7.6.2. Abbott
    • 7.6.2.1. Company overview
    • 7.6.2.2. Financial performance
    • 7.6.2.3. Product benchmarking
    • 7.6.2.4. Strategic initiatives
  • 7.6.3. Siemens Medical Solutions USA, Inc.
    • 7.6.3.1. Company overview
    • 7.6.3.2. Financial performance
    • 7.6.3.3. Product benchmarking
    • 7.6.3.4. Strategic initiatives
  • 7.6.4. QuidelOrtho Corporation
    • 7.6.4.1. Company overview
    • 7.6.4.2. Financial performance
    • 7.6.4.3. Product benchmarking
    • 7.6.4.4. Strategic initiatives
  • 7.6.5. DiaSorin S.p.A.
    • 7.6.5.1. Company overview
    • 7.6.5.2. Financial performance
    • 7.6.5.3. Product benchmarking
    • 7.6.5.4. Strategic initiatives
  • 7.6.6. Beckman Coulter, Inc.
    • 7.6.6.1. Company overview
    • 7.6.6.2. Financial performance
    • 7.6.6.3. Product benchmarking
    • 7.6.6.4. Strategic initiatives
  • 7.6.7. Quest Diagnostics Incorporated
    • 7.6.7.1. Company overview
    • 7.6.7.2. Financial performance
    • 7.6.7.3. Product benchmarking
    • 7.6.7.4. Strategic initiatives
  • 7.6.8. Labcorp
    • 7.6.8.1. Company overview
    • 7.6.8.2. Financial performance
    • 7.6.8.3. Product benchmarking
    • 7.6.8.4. Strategic initiatives
  • 7.6.9. Thermo Fisher Scientific Inc.
    • 7.6.9.1. Company overview
    • 7.6.9.2. Financial performance
    • 7.6.9.3. Product benchmarking
    • 7.6.9.4. Strategic initiatives
  • 7.6.10. Bio-Rad Laboratories, Inc.
    • 7.6.10.1. Company overview
    • 7.6.10.2. Financial performance
    • 7.6.10.3. Product benchmarking
    • 7.6.10.4. Strategic initiatives